Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed

• US 20070299687A1
• Filed: 06/23/2006
• Published: 12/27/2007
• Est. Priority Date: 06/23/2006
• Status: Abandoned Application

• Current Assignee: AcelRx Pharmaceuticals Incorporated
• Original Assignee: AcelRx Pharmaceuticals Incorporated
• Inventors: Schreck, Thomas, Palmer, Pamela, Poutiatine, Andrew I.
• Application Number:
  US11/473,551
• Publication Number:
  US 20070299687A1
• Time in Patent Office: Days
• US Class Current: 705/2
• CPC Class Codes: G16H 10/60 for patient-specific data, e.g. for electronic patient records
• CPC Class Codes: G16H 20/10 relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

A system is provided for controlled delivery of oral transmucosal medications as needed (PRN), which includes a drug delivery device having a detection mechanism for patient identification, safety features such as timed lock-out, the ability to be linked to an information network and one or more databases for storing prescription and patient usage information.

Claims

1-48. -48. (canceled)

49. A system for oral transmucosal delivery of a drug to a patient in an inpatient setting, comprising:

at least one drug delivery device for oral transmucosal drug delivery comprising a mechanism for patient identification, a lock-out means and a communication interface for bidirectional communication with an information network, wherein the patient self administers the medication on an as needed (PRN) basis.

50. The system according to claim 49, wherein said communication interface is a docking station and patient usage information is transmitted to the information network via the docking station and stored in at least one database.

51. The system according to claim 49, wherein said docking station is connected to the information network by way of a connection selected from the group consisting of a computer, a removable card, a phone line, a wireless connection and a USB port.

52. The system according to claim 49, wherein information is transmitted to, from or within said system by a communication means selected from the group consisting of a telephone, an Internet connection, a WAN network connection, a LAN network connection, a wireless connection and a satellite connection.

53. The system according to claim 49, wherein said at least one drug delivery device is connected to said information network by way of a docking station and patient usage information is transmitted to said information network and stored in at least one database.

54. The system according to claim 49, further comprising at least one input device for manually entering information into said system for delivery and monitoring delivery of said PRN medication.

55. The system according to claim 49, wherein said patient identification is accomplished using a biometric indicator selected from the group consisting of a Radio Frequency Identification (RFID) tag, a password, a pass code, fingerprint information, optical information, voice recognition, facial recognition and DNA analysis of a bodily fluid sample.

56. The system according to claim 49, wherein said oral transmucosal administration is sublingual administration.

57. The system according to claim 49, wherein said medication is used for the treatment of a condition selected from the group consisting of pain, anxiety disorders and panic attacks, nausea, insomnia, symptoms of pre-term labor and migraine.

58. The system according to claim 57, wherein the condition is pain and the drug is an opioid agonist selected from sufentanil, alfentanil and remifentanil, or a combination thereof.

59. The system according to claim 57, wherein the condition is an anxiety disorder or panic attack and the drug is a benzodiazepine.

60. The system according to claim 57, wherein the condition is nausea and the drug is selected from the group consisting of serotonin3 (5-HT3) receptor antagonists, dopamine receptor antagonists and cannabinoid receptor agonists.

61. The system according to claim 57, wherein the condition is insomnia and the drug is a benzodiazepine or non-benzodiazepine drug.

62. The system according to claim 57, wherein the condition is symptoms of pre-term labor and the drug is selected from the group consisting of beta-adrenergic receptor agonists, calcium channel blockers, and prostaglandin synthetase inhibitors.

63. The system according to claim 57, wherein the condition is symptoms of pre-term labor and the drug is.

64. The system according to claim 57, wherein the condition is migraine and the drug is selected from the ergot class and the triptan class of medications.

65. A method for oral transmucosal drug delivery of a PRN medication to a patient, comprising:

(a) providing at least one drug delivery device to said patient, wherein said drug delivery device comprises a means for patient identification, a lock-out means and a communication interface for bidirectional communication with an information network;

(b) activating said drug delivery device; and

(c) self administration of said medication on an as needed (PRN) basis by said patient.

66. The method according to claim 65, wherein said communication interface is a docking station and patient usage information is transmitted to the information network via said docking station and stored in at least one database.

67. The method according to claim 65, wherein said docking station is connected to the information network by way of a connection selected from the group consisting of a computer, a removable card or other media, a phone line, a wireless connection and a USB port.

68. The method according to claim 65, wherein said means for patient identification is a biometric indicator selected from the group consisting of an Radio Frequency Identification (RFID) tag, a password, a pass code, fingerprint information, optical information, voice recognition, facial recognition and DNA analysis of a bodily fluid sample.

69. The method according to claim 65, wherein said information network is a hospital computer system.

70. The method according to claim 65, wherein said PRN medication is used for the treatment of a condition selected from the group consisting of pain, anxiety disorders and panic attacks, nausea, insomnia, symptoms of pre-term labor and migraine.

71. The method according to claim 65, wherein the condition is pain and the drug is an opioid agonist selected from sufentanil, alfentanil and remifentanil, or a combination thereof.

72. The method according to claim 65, wherein the condition is an anxiety disorder or panic attack and the drug is a benzodiazepine.

73. The method according to claim 65, wherein the condition is symptoms of pre-term labor and the drug is terbutaline.